论文部分内容阅读
目的 :研究蛋白CD133在骨巨细胞瘤中的表达情况,进一步探索CD133与肿瘤临床病理和预后的关系,为临床判断其生物学行为及评估预后提供有力的证据。方法 :采用免疫组织化学方法检测CD133在80例骨巨细胞瘤患者术后病理标本中的表达情况。对所有数据进行χ2检验,生存分析采用Kaplan-Meier曲线进行检验。结果 :全组骨巨细胞瘤患者1、3、5年无肿瘤复发生存率分别为93.0%、88.0%,80.0%。CD133阳性和阴性的骨巨细胞瘤患者1、3、5年无肿瘤复发生存率分别为89.0%、83.0%、75.0%和99.0%、91.0%、91.0%;其差异具有统计学意义。结论 :CD133的阳性表达与骨巨细胞瘤患者预后密切关系,是评价骨巨细胞瘤恶性程度以及评估预后的重要指标。
OBJECTIVE: To study the expression of CD133 in giant cell tumor of bone, to explore the relationship between CD133 and clinical pathology and prognosis of tumor, and to provide evidence for clinical judgment of its biological behavior and prognosis. Methods: Immunohistochemical method was used to detect the expression of CD133 in 80 cases of giant cell tumor of bone after operation. All data were subjected to χ2 test, and survival analysis was tested using Kaplan-Meier curve. Results: The recurrence-free survival of patients with giant cell tumor of bone in one, three, and five years was 93.0%, 88.0% and 80.0% respectively. The recurrence-free survival rates of patients with CD133 positive and negative giant cell tumor at 1, 3 and 5 years were 89.0%, 83.0%, 75.0% and 99.0%, 91.0% and 91.0%, respectively. The difference was statistically significant. Conclusion: The positive expression of CD133 is closely related to the prognosis of patients with giant cell tumor of bone. It is an important index to evaluate the malignant degree of giant cell tumor of bone and evaluate the prognosis.